Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials
Year: 2021
Type: review
Abstract: Despite the outstanding results of treatment using autologous chimeric antigen receptor T cells (CAR-T cells) in hematological malignancies, this approach is endowed with several constraints. In particular, profound lymphopenia in some patients and the inability to manufacture products with predefined properties or set of cryopreserved batches of cells directed to different antigens in advance. Allogeneic CAR-T cells have the potential to address these issues but they can cause life-threatening graft-versus-host disease or have shorter persistence due to elimination by the host immune system. Novel strategies to create an "off the shelf" allogeneic product that would circumvent these limitations are an extensive area of research. Here we review CAR-T cell products pioneering an allogeneic approach in clinical trials.
Source: Frontiers in Immunology
Institutions: Federal Almazov North-West Medical Research Centre, Russian Academy of Sciences, Institute of Cytology, Institute of Molecular and Cell Biology, Siberian Branch of the Russian Academy of Sciences, Belarusian Research Center For Pediatric Oncology and Hematology, First Pavlov State Medical University of St. Petersburg
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,950
Awards: G1640808343, G1717111205, G6444257319
OpenAlex ID: W4200469445